NDAs and INDs Quantify the Innovation in China’s Drug R&D

Do we know how much innovation exists in China’s drug R&D sector? To get some data on the matter, the journal Nature recently published an article that counted the number of NDAs and INDs approved by the SFDA in recent years. Their answer? During the eight years from 2003-10, the SFDA allowed an average of about 25 innovative drugs each year to begin clinical trials (NDAs), and it approved for marketing about four new drugs per year (INDs). More details.... Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});